Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : SK Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
SK Biopharm and Eurofarma Submit NDA for Epilepsy Drug in Brazil
Details : Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.
Product Name : Xcopri
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 08, 2024
Lead Product(s) : Cenobamate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : SK Biopharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Recipient : HK inno.N
Deal Size : Undisclosed
Deal Type : Licensing Agreement
HK inno.N Signs Deal with Eurofarma for K-CAB Tablets
Details : Eurofarma will have the exclusive rights to develop and sell K-CAB in Brazil. HK inno.N will transfer its technology of manufacturing the treatment to the Brazilian company.
Product Name : K-CAB
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 26, 2023
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Recipient : HK inno.N
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
